FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280493952> ?p ?o ?g. }

• W4280493952 endingPage "2300" @default.
• W4280493952 startingPage "2300" @default.
• W4280493952 abstract "The impact of proton pump inhibitors (PPIs) on clinical outcomes with first-line immune checkpoint inhibitors (ICIs) in patients with metastatic melanoma was previously analyzed in the phase II study, CheckMate 069. This retrospective analysis utilized data from three phase II/III studies of first-line ICI therapy in untreated advanced melanoma: CheckMate 066, 067, and 069. All randomized patients with PPI use ≤ 30 days before initiating study treatment were included in the PPI-use subgroup. Possible associations between baseline PPI use and efficacy were evaluated within each treatment arm of each study using multivariable modeling. Approximately 20% of 1505 randomized patients across the studies reported baseline PPI use. The median follow-up was 52.6-58.5 months. Objective response rate (ORR), progression-free survival (PFS), and overall survival analyses provided insufficient evidence of a meaningful association between PPI use and efficacy outcomes with nivolumab-plus-ipilimumab, nivolumab, or ipilimumab therapy. In five of the six ICI treatment arms, 95% confidence intervals for odds ratios or hazard ratios traversed 1. Significant associations were observed in the CheckMate 069 combination arm between PPI use and poorer ORR and PFS. This multivariable analysis found insufficient evidence to support meaningful associations between PPI use and ICI efficacy in patients with advanced melanoma." @default.
• W4280493952 created "2022-05-22" @default.
• W4280493952 creator A5003348376 @default.
• W4280493952 creator A5007113702 @default.
• W4280493952 creator A5008736570 @default.
• W4280493952 creator A5009968141 @default.
• W4280493952 creator A5011325668 @default.
• W4280493952 creator A5015692829 @default.
• W4280493952 creator A5037399273 @default.
• W4280493952 creator A5048798659 @default.
• W4280493952 creator A5054656505 @default.
• W4280493952 creator A5054723003 @default.
• W4280493952 creator A5056132643 @default.
• W4280493952 creator A5076054848 @default.
• W4280493952 creator A5084967339 @default.
• W4280493952 creator A5089297467 @default.
• W4280493952 date "2022-05-05" @default.
• W4280493952 modified "2023-09-26" @default.
• W4280493952 title "Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma" @default.
• W4280493952 cites W2039123767 @default.
• W4280493952 cites W2113443314 @default.
• W4280493952 cites W2128035403 @default.
• W4280493952 cites W2128758225 @default.
• W4280493952 cites W2165456770 @default.
• W4280493952 cites W2166662937 @default.
• W4280493952 cites W2185075416 @default.
• W4280493952 cites W2194591433 @default.
• W4280493952 cites W2224656683 @default.
• W4280493952 cites W2465860350 @default.
• W4280493952 cites W2518541854 @default.
• W4280493952 cites W2519279652 @default.
• W4280493952 cites W2557336488 @default.
• W4280493952 cites W2560367415 @default.
• W4280493952 cites W2572174216 @default.
• W4280493952 cites W2626201505 @default.
• W4280493952 cites W2753432434 @default.
• W4280493952 cites W2766903152 @default.
• W4280493952 cites W2782333299 @default.
• W4280493952 cites W2799744162 @default.
• W4280493952 cites W2896600825 @default.
• W4280493952 cites W2898510820 @default.
• W4280493952 cites W2905148438 @default.
• W4280493952 cites W2912325577 @default.
• W4280493952 cites W2913368539 @default.
• W4280493952 cites W2946854701 @default.
• W4280493952 cites W2947017074 @default.
• W4280493952 cites W2947045887 @default.
• W4280493952 cites W2961862163 @default.
• W4280493952 cites W2979407980 @default.
• W4280493952 cites W3000170484 @default.
• W4280493952 cites W3000696551 @default.
• W4280493952 cites W3037219982 @default.
• W4280493952 cites W3043703771 @default.
• W4280493952 cites W3086233380 @default.
• W4280493952 cites W3087227792 @default.
• W4280493952 cites W3090469545 @default.
• W4280493952 cites W3092002669 @default.
• W4280493952 cites W3116000468 @default.
• W4280493952 cites W3143467719 @default.
• W4280493952 doi "https://doi.org/10.3390/cancers14092300" @default.
• W4280493952 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35565428" @default.
• W4280493952 hasPublicationYear "2022" @default.
• W4280493952 type Work @default.
• W4280493952 citedByCount "3" @default.
• W4280493952 countsByYear W42804939522022 @default.
• W4280493952 countsByYear W42804939522023 @default.
• W4280493952 crossrefType "journal-article" @default.
• W4280493952 hasAuthorship W4280493952A5003348376 @default.
• W4280493952 hasAuthorship W4280493952A5007113702 @default.
• W4280493952 hasAuthorship W4280493952A5008736570 @default.
• W4280493952 hasAuthorship W4280493952A5009968141 @default.
• W4280493952 hasAuthorship W4280493952A5011325668 @default.
• W4280493952 hasAuthorship W4280493952A5015692829 @default.
• W4280493952 hasAuthorship W4280493952A5037399273 @default.
• W4280493952 hasAuthorship W4280493952A5048798659 @default.
• W4280493952 hasAuthorship W4280493952A5054656505 @default.
• W4280493952 hasAuthorship W4280493952A5054723003 @default.
• W4280493952 hasAuthorship W4280493952A5056132643 @default.
• W4280493952 hasAuthorship W4280493952A5076054848 @default.
• W4280493952 hasAuthorship W4280493952A5084967339 @default.
• W4280493952 hasAuthorship W4280493952A5089297467 @default.
• W4280493952 hasBestOaLocation W42804939521 @default.
• W4280493952 hasConcept C121608353 @default.
• W4280493952 hasConcept C126322002 @default.
• W4280493952 hasConcept C143998085 @default.
• W4280493952 hasConcept C156957248 @default.
• W4280493952 hasConcept C168563851 @default.
• W4280493952 hasConcept C187960798 @default.
• W4280493952 hasConcept C207103383 @default.
• W4280493952 hasConcept C2776999253 @default.
• W4280493952 hasConcept C2777658100 @default.
• W4280493952 hasConcept C2777701055 @default.
• W4280493952 hasConcept C2780030458 @default.
• W4280493952 hasConcept C2781433595 @default.
• W4280493952 hasConcept C44249647 @default.
• W4280493952 hasConcept C502942594 @default.
• W4280493952 hasConcept C71924100 @default.
• W4280493952 hasConceptScore W4280493952C121608353 @default.

• next